Medicare holds firm on Alzheimer’s drug coverage policy

WASHINGTON — Despite pressure from Congress and advocates, Medicare isn’t changing its coverage plan for new Alzheimer’s drugs anytime soon.

Medicare on Thursday issued a statement reiterating its intent to require patient registries to collect data about how medications perform even after they gain full FDA approval. Eisai’s Leqembi could gain full approval within the next month, so time is running short for the agency to solidify details.

Read the rest…

Read Original Article: Medicare holds firm on Alzheimer’s drug coverage policy »